Press Releases Evolus, Inc.

Equities

EOLS

US30052C1071

Real-time Estimate Cboe BZX Other stock markets 10:30:49 2024-04-29 am EDT			5-day change	1st Jan Change
11.74 ^USD	+2.76%		-0.51%	+10.73%

Apr. 26	AbbVie raises annual profit forecast on strong Skyrizi sales	RE
Apr. 17	Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evolus to Report First Quarter Financial Results on May 7, 2024	Apr. 23	BU
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®	Apr. 17	BU
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Apr. 15	AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 12	BU
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Mar. 26	BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 11	AQ
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock	Mar. 11	BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 08	BU
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results, Reaffirms 2024 Guidance	Mar. 08	AQ
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance	Mar. 07	BU
Evolus Announces Results from European Head-to-Head Filler Trial	Mar. 04	AQ
Evolus Announces Results from European Head-to-Head Filler Trial	Mar. 01	BU
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences	Feb. 27	BU
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024	Feb. 22	BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 09	BU
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations, Issues 2024 Guidance	Jan. 17	AQ
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance	Jan. 16	BU
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Jan. 15	AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 12	BU
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications	Jan. 04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Evolus, Inc.

Equities

EOLS

US30052C1071

Press Releases

Filters